Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Next Previous
Trial Profile

A Phase 1 Study Of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neldaleucel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANACEA
  • Sponsors Marker Therapeutics Inc

Most Recent Events

  • 31 Mar 2025 According to a Marker Therapeutics media release, this clinical program launch is anticipated in the second half of 2025.
  • 17 Dec 2024 According to a Marker Therapeutics media release, the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support this study.
  • 14 Nov 2024 According to a Marker Therapeutics media release, the company has received a $2 million grant from the NIH in support of a Phase 1 study investigating MT-601 in CAR-relapsed patients with etastatic pancreatic cancer and The Company expects to start the clinical program of MT-601 in patients with metastatic pancreatic cancer in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top